ENZN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ENZN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-25), Enzon Pharmaceuticals's current share price is $0.07797. Enzon Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 was $0.17. Enzon Pharmaceuticals's Shiller PE Ratio for today is 0.46.
The historical rank and industry rank for Enzon Pharmaceuticals's Shiller PE Ratio or its related term are showing as below:
During the past years, Enzon Pharmaceuticals's highest Shiller PE Ratio was 7.27. The lowest was 0.35. And the median was 0.80.
ENZN's Shiller PE Ratio is ranked better thanE10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Enzon Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was $0.011. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.17 for the trailing ten years ended in Dec. 2023.
The historical data trend for Enzon Pharmaceuticals's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enzon Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Shiller PE Ratio | Get a 7-Day Free Trial | 1.16 | 1.24 | 1.01 | 0.81 | 0.56 |
For the Biotechnology subindustry, Enzon Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Enzon Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Enzon Pharmaceuticals's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
Enzon Pharmaceuticals's Shiller PE Ratio for today is calculated as
Shiller PE Ratio | = | Share Price | / | E10 |
= | 0.07797 | / | 0.17 | |
= | 0.46 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enzon Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 is calculated as:
For example, Enzon Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was:
Adj_EPS | = | Earnings per Share (Diluted) | / | CPI of Dec. 2023 (Change) | * | Current CPI (Dec. 2023) |
= | 0.011 | / | 129.4194 | * | 129.4194 | |
= | 0.011 |
Current CPI (Dec. 2023) = 129.4194.
Enzon Pharmaceuticals Quarterly Data
Earnings per Share (Diluted) | CPI | Adj_EPS | |
201403 | 0.190 | 99.695 | 0.247 |
201406 | 0.160 | 100.560 | 0.206 |
201409 | 0.170 | 100.428 | 0.219 |
201412 | 0.130 | 99.070 | 0.170 |
201503 | 0.160 | 99.621 | 0.208 |
201506 | 0.090 | 100.684 | 0.116 |
201509 | -0.040 | 100.392 | -0.052 |
201512 | 0.280 | 99.792 | 0.363 |
201603 | 0.030 | 100.470 | 0.039 |
201606 | 0.020 | 101.688 | 0.025 |
201609 | 0.020 | 101.861 | 0.025 |
201612 | -0.110 | 101.863 | -0.140 |
201703 | 0.010 | 102.862 | 0.013 |
201706 | 0.090 | 103.349 | 0.113 |
201709 | 0.003 | 104.136 | 0.004 |
201712 | 0.010 | 104.011 | 0.012 |
201803 | -0.010 | 105.290 | -0.012 |
201806 | -0.010 | 106.317 | -0.012 |
201809 | -0.010 | 106.507 | -0.012 |
201812 | 0.150 | 105.998 | 0.183 |
201903 | -0.010 | 107.251 | -0.012 |
201906 | 0.000 | 108.070 | 0.000 |
201909 | -0.010 | 108.329 | -0.012 |
201912 | 0.000 | 108.420 | 0.000 |
202003 | -0.010 | 108.902 | -0.012 |
202006 | -0.010 | 108.767 | -0.012 |
202009 | -0.010 | 109.815 | -0.012 |
202012 | -0.010 | 109.897 | -0.012 |
202103 | -0.010 | 111.754 | -0.012 |
202106 | -0.010 | 114.631 | -0.011 |
202109 | -0.010 | 115.734 | -0.011 |
202112 | -0.010 | 117.630 | -0.011 |
202203 | -0.011 | 121.301 | -0.012 |
202206 | -0.010 | 125.017 | -0.010 |
202209 | -0.010 | 125.227 | -0.010 |
202212 | 0.010 | 125.222 | 0.010 |
202303 | -0.005 | 127.348 | -0.005 |
202306 | -0.005 | 128.729 | -0.005 |
202309 | -0.003 | 129.860 | -0.003 |
202312 | 0.011 | 129.419 | 0.011 |
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Thank you for viewing the detailed overview of Enzon Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Randolph C Read | director | C/O NEW YORK REIT, INC., 405 PARK AVENUE, NEW YORK NY 10022 |
Jaffrey Adam Firestone | director | C/O CVR ENERGY, INC., 2277 PLAZA DRIVE, SUITE 500, SUGAR LAND TX 77479 |
Family Fund Couchman | other: See Footnote 1 | 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020 |
Jordan Bleznick | director | C/O ENZON PHANNACEUTICALS, INC., 120 COMMERCE DRIVE (SUITE 135), CRANFORD NJ 07016 |
Pearce Michael Cooper | other: See explanation of responses | 213 RHODODENDRON DRIVE, CHAPEL HILL NC 27517 |
Harper Asset Management Llc | other: See explanation of responses | 2945 S CENTER GREEN CT, G215, BOULDER CO 80301 |
Brian James Harper | other: See explanation of responses | 6680 GUNPARK DRIVE, SUITE 202B, BOULDER CO 80301 |
Myrexis, Inc. | other: See Footnote 1 | 600 FIFTH AVENUE, 2ND FLOOR, NEW YORK NY 10020 |
Xstelos Corp. | other: See Footnote 1 | 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020 |
Jonathan Couchman | 10 percent owner, other: See Footnote 1 | 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020 |
Carl C Icahn | 10 percent owner | C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH-1, SUNNY ISLES BEACH FL 33160 |
Richard L Feinstein | officer: VP-Finance and PFO | |
Jonathan Christodoro | director | C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH, SUNNY ISLES FL 33160 |
Kostas D Odysseas | director | 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
Jennifer Isacoff Mcnealey | director | C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO Z4 92121 |
From GuruFocus
By guruek guruek • 11-15-2009
By Holly LaFon Holly LaFon • 01-10-2014
By Sydnee Gatewood Sydnee Gatewood • 12-02-2016
By Sheila Dang Sheila Dang • 06-23-2015
By gurufocus • 02-13-2010
By Marketwired Marketwired • 08-22-2020
By gurufocus 10qk • 05-10-2010
By Marketwired Marketwired • 01-04-2021
By gurufocus 10qk • 11-04-2010
By gurufocus Todd Sullivan • 03-14-2008